NEW YORK — (BUSINESS WIRE) — Cytovia, the oncology subsidiary of Immune Pharmaceuticals (IMNP) (“Immune” or the “Company”), a clinical stage biopharmaceutical company, today announced the publication of new results supporting the benefits of its lead compound Ceplene® (histamine dihydrochloride). In parallel, Cytovia has filed a world-wide patent to protect the use of Ceplene® in CML. In the British Journal of Haematology new publication (https://www.ncbi.nlm.nih.gov/pubmed/28542840), the authors show that the genetic elimination of NOX2 function delayed the development of CML in mice and prolonged survival. These results support that Ceplene®, or other inhibitors of NOX2 function, may be efficacious in CML.